Effectiveness and Safety of Low Dose of Tenofovir Disoproxil Fumarate in Malagasy Patients with Chronic Hepatitis B

Table 4

Analysis of the predictive factors for a CVR after 3 months of TDF.

Variables	HR	CI (95%)	value
Age
[30–40[	0.35	0.07–1.55	0.167
[40–50[	0.38	0.10–1.49	0.165
[50–60[	0.48	0.10–2.20	0.345
[60–70[	0.33	0.05–1.50	0.99
Gender, female	0.67	0.25–1.59	0.365
Fibrosis status
F1	1.83	0.29–11.40	0.515
F2	2.00	0.32–12.65	0.462
F3	1.77	0.11–27.45	0.654
F4	1.83	0.22–15.60	0.679
HBV-DNA (IU/mL)
2000–20,000	0.95	0.15–4.97	0.945
≥20,000	0.14	0.02–0.92	0.041
ALT (IU/L)
[40-80[	0.93	0.30–2.57	0.599
≥80	0.76	0.24–2.44	0.649
HBeAg-positive	0.83	0.28–2.45	0.731
NA-experienced therapy
Lamivudine-experienced	0.74	0.26–2.13	0.65
Full-dose tenofovir experienced	0.88	0.10–7.65	0.905

HR: hazard ratio; CI: confidence interval; ALT: alanine aminotransferase; HBeAg: hepatitis B e antigen; NA: nucleos(t)ide analog.